Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Bertrand, Dufour"'
Autor:
S. Kreps, Safia Maraadji, Yves Chrétien, P. Giraud, Martin Housset, Jean-Emmanuel Bibault, Nicolas Thiounn, Antoine Smulevici, Bertrand Dufour, Catherine Durdux, A. Mejean, E. Fabiano
To evaluate trimodal conservative treatment as an alternative to radical surgery for urothelial muscle-invasive bladder cancer (MIBC). This retrospective study reported the carcinologic and functional results of patients (pts) presenting a cT2/T3 N0M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91734db89130421a02e932dde23bb269
Autor:
Bertrand Dufour
Publikováno v:
Bulletin de l'Académie Nationale de Médecine. 193:691-708
RESUME Le cancer du rein represente 3 % de la totalite des cancers ; il est encore trop souvent diagnostique tardivement et la necessaire nephrectomie elargie a un pronostic d’ensemble mediocre de 70 % a cinq ans. Grâce aux progres extraordinaires
Autor:
Arnaud Mejean, E. Fontaine, Marc-Olivier Timsit, Nicolas Thiounn, Bertrand Dufour, Yves Chretien, Jean-Philippe Bazin
Publikováno v:
Urology. 67:923-926
Objectives To evaluate prospectively a healthy parenchymal safety margin during conservative surgery for renal cell carcinoma. Methods From 1997 to 2001, elective nephron-sparing surgery was performed through a flank incision in 61 consecutive patien
Autor:
Morgan, Roupret, Vincent, Hopirtean, Arnaud, Mejean, Nicolas, Thiounn, Bertrand, Dufour, Yves, Chretien, Dominique, Chauveau, Stephane, Richard
Publikováno v:
Journal of Urology. 170:1752-1755
We reviewed the efficacy and safety of nephron sparing surgery for renal cell carcinoma in patients with von Hippel-Lindau disease.Data were collated for all 56 patients with a mean age of 37.2 +/- 11.3 years (range 14 to 62) with von Hippel-Lindau d
Autor:
Jean Philippe Bazin, Arnaud Mejean, Nicolas Thiounn, Hubert Benoit, Bertrand Dufour, Yves Chretien, Frédérique Larousserie, Vincent Hopirtean
Publikováno v:
Journal of Urology. 170:764-767
We identified prognostic factors of papillary renal cell carcinoma (PRCC) types 1 (PRCC1) and 2 (PRCC2).Between 1985 and 1998, 759 patients underwent surgery for renal cell carcinoma, of whom 88 (11.6%), including 69 males and 19 females with a mean
Autor:
Arnaud Mejean, Vincent Hopirtean, Morgan Rouprêt, Bertrand Dufour, Nicolas Thiounn, Frédérique Larousserie
Publikováno v:
Journal of Urology. 169:1287-1290
We describe diagnostic and therapeutic characteristics, and long-term followup of collecting (Bellini) duct carcinoma.Ten patients underwent surgery, including radical nephrectomy in 9 and partial nephrectomy in 1, for collecting duct carcinoma diagn
Autor:
Chant Balian, Yves Chretien, Bertrand Dufour, Sebastien Cazin, Nicolas Thiounn, Benoît Vogt, Arnaud Mejean
Publikováno v:
Urology. 59:358-361
Objectives To determine whether coloepiploic mobilization (CEM) is indicated to reduce the incidence of iatrogenic splenectomy during left radical nephrectomy for renal cell carcinoma. The incidence of iatrogenic splenectomy during a left nephrectomy
Publikováno v:
EMC - Urología. 34:1-10
Resumen El sacrificio al que se somete al paciente por la ablacion vesical o la perdida de la funcion vesical como reservorio ha impulsado a muchos equipos quirurgicos a buscar medios mas fisiologicos de derivarla orina. Prueba de esto son las entero
Autor:
Bertrand Dufour, X. Belin, B. Debre, Yves Chretien, Olivier Hélénon, J. M. Casanova, Moreau Jf, François Cornud, Nicolas Thiounn, Thierry Flam, F Paraf, Deslignières S
Publikováno v:
Scopus-Elsevier
Objective To evaluate the accuracy of endorectal magnetic resonance imaging (MRI) with fast spin-echo sequences in the local staging of clinically localized prostate cancer. Patients and methods Seventy-one patients with a clinical T1 (18 patients) o
Autor:
Sylvie Delanian, Bertrand Dufour, Yves Chrétien, Martin Housset, Christophe Hennequin, Catherine Maulard-Durdux
Publikováno v:
Cancer. 77:1144-1148
BACKGROUND Hormonotherapy temporarily controls symptoms in 80% of patients with metastatic prostate carcinoma. Once progression occurs, no consensus exists on further therapy. Oral etoposide (VP–16) has shown clinical efficacy in advanced small cel